News | March 10, 2026
GAIA and Daiichi Sankyo Europe join forces to launch groundbreaking digital therapeutic for heart health
Germany will be the first launch market
Germany will be the first launch market
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
Huwel’s diagnostic solutions leverage open RT-PCR system
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations
The company will address the observations and respond to the U.S. FDA within the stipulated timeframe
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
Subscribe To Our Newsletter & Stay Updated
